Phenylacetic Acid

Phenylacetic Acid

SCHEMBL1685642

O=C([O-])Cc1ccccc1.O=C([O-])Cc1ccccc1.O=C([O-])Cc1ccccc1.[Rh+3]

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 3/20 0.71
CES2 O00748 2/20 0.71
AKR1B1 P15121 1/20 0.64
FNTA P49354 1/20 0.58
FNTB P49356 1/20 0.58
HDAC8 Q9BY41 2/20 0.54
HDAC6 Q9UBN7 2/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
HDAC3 O15379 1/20 0.54
HDAC4 P56524 1/20 0.54
HDAC1 Q13547 1/20 0.54
HDAC7 Q8WUI4 1/20 0.54
HDAC2 Q92769 1/20 0.54
HDAC10 Q969S8 1/20 0.54
HDAC11 Q96DB2 1/20 0.54
HDAC9 Q9UKV0 1/20 0.54
HDAC5 Q9UQL6 1/20 0.54
ALDH1A1 P00352 1/20 0.50
MAPK1 P28482 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylacetic Acid SCHEMBL534930 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL62440 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL78312 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL3477184 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL6547052 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL6930085 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL11772449 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL7214226 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL11248694 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB
Phenylacetic Acid SCHEMBL8410217 0.95 CES1 (0.71) CES1CES2AKR1B1FNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118496244-A Rhodium catalyzed C-H cyclization construction of pyridophenothiazine/oxa/selenazinium salt organic single molecule white light material 重庆大学 2024-08-16 CN claimed
CN-114195820-B Isoserine derivative, preparation thereof and application thereof in taxol synthesis 中山大学 2023-11-10 CN claimed
CN-116283534-A Multifunctional chiral eneyne ligand and preparation method and application thereof 中国石油化工股份有限公司 2023-06-23 CN claimed
CN-114195820-A Isoserine derivative, preparation thereof and application thereof in synthesis of paclitaxel 中山大学 2022-03-18 CN claimed
US-20240389593-A1 HETEROCYCLIC COMPOUND AND USE THEREOF KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 2024-11-28 US disclosed
CN-118496244-A Rhodium catalyzed C-H cyclization construction of pyridophenothiazine/oxa/selenazinium salt organic single molecule white light material 重庆大学 2024-08-16 CN disclosed
EP-4317160-A1 HETEROCYCLIC COMPOUND AND USE THEREOF Kumiai Chemical Industry Co., Ltd. (JP) 2024-02-07 EP disclosed
CN-114195820-B Isoserine derivative, preparation thereof and application thereof in taxol synthesis 中山大学 2023-11-10 CN disclosed
CN-116283534-A Multifunctional chiral eneyne ligand and preparation method and application thereof 中国石油化工股份有限公司 2023-06-23 CN disclosed
CN-114195820-A Isoserine derivative, preparation thereof and application thereof in synthesis of paclitaxel 中山大学 2022-03-18 CN disclosed
EP-1950208-B1 PROCESS FOR PRODUCING 6,6-DIMETHYL-3-OXABICYCLO[3.1.0]HEXAN-2-ONE SUMITOMO CHEMICAL CO (JP) 2012-05-02 EP disclosed
US-7928253-B2 Method of producing 6,6-dimethyl-3-oxabicyclo[3.1.0]hexan-2-one SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-04-19 US disclosed
US-7186709-B2 Subjecting a vinyl ethers and an unsaturated ketoester to suitable conditions to generate a scaffold having the core dihydropyrancarboxamide or dihydropyrancarboxylic ester or acid; anticarcinogenic agents PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2007-03-06 US disclosed
US-7109377-B2 Synthesis of combinatorial libraries of compounds reminiscent of natural products PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2006-09-19 US disclosed
US-20040214232-A1 Generation of skeletal diversity within a combinatorial library HOWARD HUGHES MEDICAL INSTITUTE 2004-10-28 US disclosed
US-20040059138-A1 Dihydropyrancarboxamides and uses thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2004-03-25 US disclosed
US-20040014168-A1 Reagents and methods for library synthesis and screening HOWARD HUGHES MEDICAL INSTITUTE 2004-01-22 US disclosed
US-6448443-B1 GENERATED FROM DIVERSIFIABLE SCAFFOLDS SYNTHESIZED FROM THE PYRIDINE-BASED TEMPLATE ISONICOTINAMIDE; ALSO PROVIDES A NOVEL ORTHO-NITROBENZYL PHOTOLINKER; SYNTHESIZED FROM A SHIKIMIC ACID BASED EPOXYOL TEMPLATE PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2002-09-10 US disclosed
WO-2000006525-A9 SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS HARVARD COLLEGE (US) 2000-04-20 WO disclosed
WO-2000006525-A2 SYNTHESIS OF COMBINATORIAL LIBRARIES OF COMPOUNDS REMINISCENT OF NATURAL PRODUCTS PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2000-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040059138-A1 Dihydropyrancarboxamides and uses thereof CCNA1, DPYD, DHFR CES1 220/4885CES2 994/4885AKR1B1 227/4885
US-20240389593-A1 HETEROCYCLIC COMPOUND AND USE THEREOF C1S, C3AR1, CBR3 CES1 498/4885CES2 456/4885AKR1B1 332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.